// App-Quantinova.ai

: A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT.

Researchers

Presenter

  • Renuka V. Iyer

Principal Investigators

  • Michael Petroziello

  • Nainesh Parikh

  • Richard D. Kim

  • Thatcher Ross Heumann

  • Daniel Brown

  • Kevin Kim

  • Yixing Jiang

  • Suvranu Ganguli

  • Eric Marks

  • Beau Toskich

  • Umair Majeed

  • Shamar Young

  • Rachna T. Shroff

  • Moh'd M. Khushman

  • Andrew Gunn

  • Filip Banovac

  • Aiwu Ruth He

Medical Centers

  • University of Arizona Cancer Center, Tucson, AZ

  • University of Alabama at Birmingham, Birmingham, AL

  • Vanderbilt University, Nashville, TN

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Boston Medical Center and Boston University School of Medicine, Boston, MA

  • Mayo Clinic Division of Vascular/Interventional Radiology, Jacksonville, FL

  • University of Maryland, Baltimore, MD

  • University of Alabama at Birmingham School of Medicine, Birmingham, AL

  • Georgetown University Medical Center, Washington, DC

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • University of Minnesota, Minneapolis, MN

  • Mayo Clinic, Jacksonville, FL

  • Roswell Park Cancer Institute, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04541173

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved